News

In extensive preclinical studies, VEL-0230 proved to be a powerful anti-inflammatory agent that also stimulates bone formation and inhibits bone loss. Taken together, these characteristics strongly suggest this

The company may sell up to $10 million of its common stock to Fusion Capital from time to time over a 25-month period after the Securities and Exchange

For the past four years, Mr Hoffman has served as executive vice president, general counsel, secretary and CFO at Encorium Group (formerly Covalent Group). There he added shareholder

The Phase II trial will enroll up to 40 patients. TLN-4601 will be continuously administered intravenously over a 21 day cycle, consisting of 14 days on treatment and

Under the terms of the merger agreement, the consideration will be paid in cash and stock. Iomai’s public shareholders, representing approximately 59% of Iomai’s outstanding common stock will

Taclonex Scalp (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is called Xamiol outside the US. Warner Chilcott is Leo Pharma’s exclusive licensee of Taclonex and Dovonex products in the

The orphan drug designation provides eligibility for a seven-year period of market exclusivity in the US after product approval, an accelerated review process, grant funding, tax benefits, and

Gross profit was $70.1 million, or 47% of net revenues for the first quarter of 2008, compared with $65.4 million, or 47% of net revenues, in the first

The company’s platform ECM Technology, an extracellular matrix biomaterial, is said to provide a natural bioscaffold that enables a patient’s own host cells to repopulate and repair damaged